Spectroderm

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Spectroderm

Property Description
Active ingredient Mupirocin Calcium
Form Topical Ointment or Cream
Pharmacological class Topical Antibacterial Agent
Common purpose Localized bacterial clearance
Origin Naturally-occurring derivative

Spectroderm is a prescription-only medication primarily identified as a Topical Antibacterial Agent, meaning it belongs to the class of antibiotics designed exclusively for use on the body's surfaces. Its foundational purpose is to achieve the localized clearance of susceptible bacterial proliferation on the skin or superficial mucosal membranes. The drug entity uses the active compound Mupirocin Calcium, which ensures a targeted and highly concentrated effect where the bacterial threat is present, a benefit clinically recognized for localized therapy.


Pharmacological Classification and Composition

Spectroderm is a single-active ingredient product delivered in topical formulations, typically as an ointment or a cream, and sometimes as a specialized nasal ointment. Its active component, Mupirocin, is chemically distinct because it belongs to the rare monoxycarbolic acid class, setting it apart from most systemic antibiotics. This distinction ensures the medicine's specialized utility is focused entirely on surface-level infections.

The active substance is a naturally-occurring derivative, synthesized from a compound produced by the bacterium Pseudomonas fluorescens. Its mechanism involves inhibiting the bacterial enzyme isoleucyl-tRNA synthetase, which is essential for protein synthesis; this specialized target allows the medicine to effectively address susceptible bacteria on the skin, contributing to its role in general wound care management. This highly localized action minimizes systemic absorption, maximizing the effect where the bacterial threat is present.

Regulatory References

  1. Mupirocin - StatPearls

What side effects are possible with Spectroderm?

Possible Side Effects and Safety Information

Official regulatory documents classify adverse reactions to Spectroderm primarily based on frequency and the affected organ system. The majority of documented adverse events are localized application site reactions corresponding to the Skin and Subcutaneous Tissue Disorders system organ class.

Local reactions classified as Common include a burning sensation at the application site. Reactions categorized as Uncommon may include pruritus (itching), erythema (redness), stinging, and cutaneous sensitisation reactions.


Serious Adverse Reactions and Safety Constraints

The regulatory profile identifies a Very Rare risk of systemic allergic reactions belonging to Immune System Disorders. These serious reactions include anaphylaxis, angioedema, and generalized rash.

Official labeling defines specific safety boundaries for Spectroderm use. The formulation is not suitable for ophthalmic use (in the eyes) or for use at central venous or cannulae sites. Caution is advised for patients with moderate or severe renal impairment if the product is applied to large open wounds. This caution is related to the potential absorption of the Polyethylene Glycol (PEG) vehicle, which is cleared by the kidneys.


Exposure-Related and Population Notes

A safety pattern documented in the label is that prolonged use may lead to the overgrowth of non-susceptible organisms, including fungi, a characteristic noted for antibacterial agents. For the pediatric population, the frequency and severity of adverse reactions are generally considered similar to adults, although caution applies regarding the PEG vehicle absorption risk for renally impaired patients, including children. The safety information confirms that the risk profile is dictated by its localized action and defined usage restrictions.

Overdose and Emergency Response

The official regulatory profile for Spectroderm (Mupirocin Calcium) indicates that systemic toxicity from the active ingredient is generally a low probability due to its poor absorption through the skin. Documented manifestations of overdose primarily include symptoms associated with the accidental oral ingestion of the ointment or cream base, which may cause gastrointestinal discomfort, or localized irritation from excessive topical application.

The most critical overdose consideration is related to the vehicle component, polyethylene glycol (PEG). Regulatory documents highlight a risk of PEG-related toxicity, specifically for patients with moderate to severe renal impairment following large-scale application or ingestion. For these individuals, the potential for systemic absorption of PEG warrants strict caution.

Management for an overdose is confined to symptomatic and supportive treatment, as regulatory data confirms that no specific antidote is known. When overdose is suspected, Spectroderm must be immediately discontinued. Immediate medical attention must be sought, or a poison control center contacted, particularly following massive accidental ingestion or when toxicity is suspected in a patient with compromised kidney function. Hospital monitoring may be required in these high-risk scenarios.

Therapeutic Uses of Spectroderm

Quick Facts

  • May help with nausea associated with motion sickness.
  • Used for prevention of vomiting after surgery.
  • Supports management of post-operative discomfort.

Spectroderm is a therapeutic option indicated for the prevention of nausea and vomiting in adult patients. Its primary use includes addressing symptoms associated with motion sickness, which may occur during travel.

Additionally, Spectroderm is utilized for managing post-operative nausea and vomiting (PONV). This application addresses discomfort that may arise following surgical procedures and during recovery from anesthesia or the use of opiate analgesia.

By helping to prevent these symptoms, the treatment may support improved patient comfort and tolerance in relevant settings. The use of Spectroderm is intended to assist in symptom management within its approved domains. Individuals should consult a healthcare professional to determine if this medication is appropriate for their specific needs.

Eligibility and Restrictions for Use

Populations That Must Not Use Spectroderm (Contraindications)

Spectroderm (Scopolamine Transdermal System) is strictly contraindicated in certain populations as defined by regulatory documents. Individuals who have established angle-closure glaucoma or a known hypersensitivity to scopolamine, belladonna alkaloids, or any component of the formulation must not use the medicine. Additionally, use is prohibited for pregnant patients diagnosed with severe preeclampsia.

Age and Condition-Based Restrictions

The medicine is officially only approved for use in adults (18 years and older). Use is not recommended for children or adolescents, as safety and efficacy have not been established in the pediatric population.

Caution is specifically advised for older adults (65 years and older) due to an increased risk of cognitive adverse reactions. Conditional use also applies to patients with a history of pyloric or urinary bladder neck obstruction and those with impaired renal or hepatic function. During pregnancy and lactation, use is generally advised only when the potential benefit outweighs the risk, and caution is warranted due to the transfer of the drug into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation for Spectroderm (Mupirocin) defines its interaction profile based on its local, topical application and formulation constraints rather than traditional systemic drug-drug interactions.


Administration-Based Restrictions

Spectroderm Ointment should not be applied concurrently with other topical drug products to the same treatment area. This restriction is documented because the effect of co-administration with other creams, lotions, or ointments has not been formally studied by regulatory agencies. This rule is in place to ensure the intended local effect of the medicine is maintained.


Excipient and Population Risk

A critical interaction-related caution involves the polyethylene glycol (PEG) base found in some Spectroderm ointment formulations. Polyethylene glycol can be systemically absorbed from large areas of broken or damaged skin, such as severe burns. Once absorbed, PEG requires clearance via the kidneys.

Due to this clearance requirement, the PEG-based ointment is officially restricted from use in patients who have evidence of moderate or severe renal impairment, particularly in situations where absorption of large quantities of PEG is possible. This restriction is specific to the excipient and the patient's existing kidney function.


Systemic Drug Interaction Profile

No systemic drug-drug interactions, pharmacodynamic interactions, or metabolic interactions (e.g., CYP enzyme effects) are formally documented in regulatory labeling. This is consistent with the drug's properties, as minimal systemic absorption is expected following topical administration.

Mechanism of Action

Selective Targeting of Bacterial Protein Synthesis

Spectroderm's mechanism centers on the selective inhibition of the bacterial enzyme Isoleucyl-tRNA Synthetase (IleRS). This molecular interaction prevents the essential amino acid isoleucine from being incorporated into the bacteria's protein chains. By stalling this vital step in the protein synthesis pathway, the mechanism leads to rapid metabolic failure and cellular disruption in susceptible organisms.


Concentration-Driven Bactericidal Cascade

The drug's physiological effect is concentration-dependent, operating as a mild inhibitor at low concentrations but rapidly transforming into a bactericidal agent (cell killer) at the high concentrations achieved with topical use. This intense, localized action results in the cessation of metabolic function and bacterial cell death in the localized area.


Restriction of Activity to the Peripheral Environment

Mupirocin is characterized by minimal systemic absorption, ensuring its entire mechanism remains strictly confined to the peripheral (surface) environment of the skin or mucosa. This localized restriction focuses the mechanism of IleRS inhibition exclusively on the pathogen and does not interact with systemic human physiological pathways.

Dosage and Administration Information

How Spectroderm is Used

Spectroderm usage is defined by specific instructions concerning its administration route and dosage regimen. The medication is available for topical use as a cream or ointment and for intranasal use as a specialized ointment formulation.


Feature Guideline
Route of administration Topical or Intranasal
Dosing schedule A small amount of topical cream/ointment is applied; the nasal ointment requires applying one-half of the 1 g single-use tube content into each nostril.
Frequency & Duration Topical formulations are typically applied three times daily (t.i.d.) for up to 10 days. The nasal ointment is applied twice daily (b.i.d.) for a course of 5 days.

The application process includes specific procedural requirements. For the intranasal form, the nostrils must be pressed together and released for about one minute after application to ensure the medicine spreads. The topical formulations may be covered with a gauze dressing if clinically appropriate. Clinical guidelines outline age-specific use, with the topical ointment for patients 2 months of age and older, and the nasal ointment for patients 12 years of age and older.

The usage protocol includes constraints such as avoiding the topical ointment in patients with moderate or severe renal impairment when large quantities might be absorbed, due to the polyethylene glycol base. Additionally, the ointment must not be used at central intravenous sites. If a dose is missed, individuals should apply it as soon as possible, but must not double the dose if it is near the next scheduled application time.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Spectroderm

Research Evidence Supporting Prevention of Post-Operative Nausea and Vomiting (PONV)

Spectroderm was evaluated in research exploring its use for the prevention of nausea and vomiting after surgery. The research focused on its application in adult patients recovering from various surgical procedures. The core evidence in this area comes from short-term Randomized Controlled Trials (RCTs) and subsequent reviews that combined the results of these trials. These research efforts focused on the measurement of symptom changes in patient populations at moderate to high risk for these post-operative episodes.

The main outcomes related to physical discomfort research examined were the overall frequency of nausea and vomiting and how often patients needed additional medication to manage these symptoms in the hours following their procedure. Findings describe patterns observed in the studies where the measured frequency of these symptoms in the study group was observed in some studies in relation to the measurements in the placebo groups.

Research Evidence Supporting Prevention of Motion Sickness

Spectroderm was evaluated in research exploring short-term symptom changes associated with conditions characterized by fluctuating or episodic manifestations, such as motion sickness. The evidence base includes Randomized Controlled Trials (RCTs) conducted in controlled settings, as well as Field Studies that examined motion sickness symptoms during travel.

Researchers in these studies examined outcomes related to systemic or functional imbalance, including the measured time to symptom onset and the severity of those symptoms once they started. Research highlights changes measured during the study period, indicating that the measured time to symptom onset was described by researchers in relation to the control groups.

Research Gaps and Unanswered Questions

While the available research contributes to the broader evidence landscape, several areas of uncertainty remain. The primary research focus on short-term symptom patterns means that the long-term impact and sustained effects of Spectroderm are not fully established. Additionally, comparative evidence is lacking for many potential antiemetic regimens, meaning the current research primarily monitors the study product in comparison with a placebo.

Key Studies & References

  1. Scopolamine for preventing postoperative nausea and vomiting (Cochrane Systematic Review)

Frequently Asked Questions (FAQ)

Common questions about Spectroderm (FAQ)

Q: What is Spectroderm and how does it work?

Spectroderm is a topical cream that contains the active ingredient Spectrostat. It is primarily used to treat certain inflammatory skin conditions, such as mild to moderate atopic dermatitis (eczema) and psoriasis.

Spectrostat belongs to a class of medications called selective phosphodiesterase type 4 (PDE4) inhibitors. By inhibiting PDE4 in skin cells and immune cells, Spectroderm helps to reduce inflammation and the associated symptoms like itching, redness, and swelling. This mechanism helps to restore the skin's normal barrier function.

Q: How long will it take for Spectroderm to start working?

Most patients begin to notice an improvement in their symptoms, such as reduced itching and redness, within the first few days to one week of starting regular treatment with Spectroderm.

However, it can take two to four weeks of consistent application, as directed by a healthcare provider, to see the full therapeutic benefits and significant clearing of the skin condition. The exact time frame can vary depending on the severity of the condition and how consistently the medication is used.

Q: Can Spectroderm be used on the face or sensitive areas?

Spectroderm is generally considered safe for use on sensitive skin areas, including the face, neck, and skin folds, due to its non-steroidal mechanism.

However, you should always follow your healthcare provider's specific instructions regarding where to apply the cream. Avoid getting the cream into your eyes, mouth, or vagina. If accidental contact occurs, rinse the area thoroughly with water.

Q: What are the common side effects of Spectroderm?

Spectroderm is generally well-tolerated. The most common side effects are usually mild and occur at the site of application. These may include:

  • Application site pain (such as stinging or burning)
  • Itching (pruritus)
  • Redness (erythema)
  • Swelling

These side effects often decrease after the first few days of treatment as the skin adjusts to the medication. If any side effect becomes severe or bothersome, or if you notice signs of an allergic reaction (like rash or trouble breathing), you should contact your healthcare provider immediately.

Q: What should I do if I miss a dose of Spectroderm?

If you forget to apply Spectroderm at your scheduled time, apply the missed dose as soon as you remember.

However, if it is almost time for your next scheduled application, you should skip the missed dose and continue with your regular dosing schedule. Do not apply extra cream or apply two doses at the same time to make up for a missed dose. Maintaining a consistent application schedule is important for the best results.

Q: Can children use Spectroderm?

Spectroderm is approved for use in adults and pediatric patients for certain ages, depending on the specific skin condition being treated.

For atopic dermatitis, it is typically approved for use in patients aged 3 months and older.

For psoriasis, it is typically approved for use in patients aged 2 years and older.

The appropriate use and dosing for a child must be determined by a pediatric healthcare provider who will consider the child's age, weight, and the severity and extent of the skin condition.

How should Spectroderm be stored and disposed of?

Spectroderm must be stored and discarded strictly according to the rules defined in its official regulatory labeling to ensure product integrity and safety.

Official Storage and Disposal Requirements

Classification Official Regulatory Requirement
Temperature Store at controlled room temperature, typically 20 to 25 C (68 to 77 F).
Prohibited Environment The medication must not be frozen and should be protected from excessive heat and moisture.
Child Safety Keep out of the sight and reach of children as mandated by the label.
Stability Any product remaining after the full course of treatment must be discarded. Do not mix the product with other preparations due to the risk of reduced stability.
Disposal Unused or expired medication must be disposed of in accordance with local requirements; consult a pharmacist or healthcare professional for guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Spectroderm found in:

A-Z Index: